Dopamine regulates cell cycle regulatory proteins via cAMP, Ca(2+)/PKC, MAPKs, and NF-kappaB in mouse embryonic stem

Min Young Lee1, Jung Sun Heo, Ho Jae Han

  • 1Department of Veterinary Physiology, College of Veterinary Medicine, Chonnam National University, Gwangju, Korea.

Insights

Dopamine significantly inhibits DNA synthesis in mouse embryonic stem cells. This effect is mediated through complex signaling pathways including cyclic adenosine monophosphate, calcium/protein kinase C, mitogen-activated protein kinases, and nuclear factor-kappaB.

Area of Science:

  • Molecular Biology
  • Stem Cell Biology
  • Neuroscience

Background:

  • Dopamine's role in cellular processes beyond neurotransmission is an area of ongoing research.
  • Embryonic stem cells (ESCs) possess unique properties of self-renewal and differentiation, making them crucial for developmental studies.
  • Understanding the molecular mechanisms regulating DNA synthesis in ESCs is fundamental for regenerative medicine and developmental biology.

Purpose of the Study:

  • To investigate the impact of dopamine on DNA synthesis in mouse embryonic stem cells.
  • To elucidate the specific intracellular signaling cascades involved in dopamine's effect on DNA synthesis.
  • To identify the key molecular players and pathways mediating dopamine's influence on ESC proliferation.

Main Methods:

  • Assessed DNA synthesis using [(3)H]-thymidine incorporation in mouse ESCs.
  • Utilized receptor agonists (SKF 38393 for D1, quinpirole for D2) and antagonists to probe dopamine receptor involvement.
  • Measured intracellular signaling molecules including cyclic adenosine 3, 5-monophosphate (cAMP), intracellular calcium ([Ca(2+)](i)), protein kinase C (PKC) translocation, mitogen-activated protein kinases (MAPKs) phosphorylation, and reactive oxygen species (H(2)O(2)).
  • Analyzed the expression of cell cycle regulatory proteins (cyclin E, CDK-2, cyclin D1, CDK-4) and activated transcription factors (NF-kappaB).
  • Employed pharmacological inhibitors for various signaling pathways (adenylyl cyclase, phospholipase C, PKC, MAPKs) and G protein signaling (pertussis toxin).

Main Results:

  • Dopamine significantly inhibited DNA synthesis in mouse ESCs in a dose- and time-dependent manner.
  • Dopamine, D1 and D2 receptor agonists reduced [(3)H]-thymidine incorporation, indicating receptor-mediated effects.
  • Dopamine modulated intracellular signaling, including increased cAMP (via D1), PKC translocation, elevated [Ca(2+)](i), enhanced MAPK phosphorylation (p44/42, p38, JNK), increased H(2)O(2) formation, and NF-kappaB activation.
  • Dopamine treatment led to decreased levels of key cell cycle proteins (cyclin E, CDK-2, cyclin D1, CDK-4).
  • Inhibitors of cAMP, Ca(2+)/PKC, MAPKs, NF-kappaB, and G protein signaling blocked the dopamine-induced inhibition of cell cycle proteins and DNA synthesis.

Conclusions:

  • Dopamine exerts an inhibitory effect on DNA synthesis in mouse embryonic stem cells.
  • This inhibition is mediated through multiple signaling pathways: cyclic adenosine monophosphate (cAMP), calcium/protein kinase C (Ca(2+)/PKC), mitogen-activated protein kinases (MAPKs), and nuclear factor-kappaB (NF-kappaB).
  • The findings reveal a novel role for dopamine in regulating ESC proliferation via intricate molecular signaling networks.

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...